Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 4/20 | 0.65 |
| ▸ | EGFR | P00533 | 5/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.47 |
| ▸ | ULK1 | O75385 | 3/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151152 | 0.81 | ZAP70 (0.66) | ZAP70EGFRPTK2ULK1ALK | |
| SCHEMBL5291249 | 0.80 | ALK (0.48) | ZAP70EGFRPTK2ALKIGF1R | |
| SCHEMBL1078874 | 0.80 | PRKCQ (0.49) | ZAP70PTK2ALKIGF1RMAPT | |
| SCHEMBL5284485 | 0.80 | ZAP70 (0.45) | ZAP70EGFRPTK2ULK1ALK | |
| SCHEMBL12856125 | 0.80 | ZAP70 (0.81) | ZAP70EGFRPTK2ULK1ALK | |
| SCHEMBL375886 | 0.79 | ZAP70 (1.00) | ZAP70EGFRPTK2ULK1ALK | |
| SCHEMBL1707654 | 0.77 | ZAP70 (0.73) | ZAP70EGFRPTK2ALK | |
| SCHEMBL382125 | 0.76 | EGFR (0.69) | ZAP70EGFRALKIGF1R | |
| SCHEMBL12780617 | 0.71 | ZAP70 (0.68) | ZAP70EGFRPTK2ULK1ALK | |
| SCHEMBL12780619 | 0.70 | ZAP70 (0.69) | ZAP70EGFRPTK2ULK1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606265-A1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | Novartis AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080980-A1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2004-09-23 | — | — | WO | disclosed |